Hypnotherapy for Irritable Bowel Syndrome Anno 2019 Daniel
Hypnotherapy for Irritable Bowel Syndrome Anno 2019 Daniel Keszthelyi MD Ph. D Gastroenterologist Maastricht University Medical Center
Disclosures 23 rd March 2019 Research funding: Will Pharma BV, Grünenthal Gmb. H, Allergan Ltd. Speaker: Will Pharma BV, Grünenthal Gmb. H Advisory board: Bayer Gmb. H, Biocodex Benelux
Prof Peter Whorwell BSc MB BS MD Ph. D FRCP
The evidence: meta-analyses 1. Ford et al. 2014 (Am J Gastroenterol): 5 studies with 278 patients -> NNT of 4 (confidence interval 3 -8). Re-analysis with the same data (Ford et al. Am J Gastroenterol 2019): NNT 5 (CI 3. 5 -10) 2. Schaefert et al. 2014 (Psychosom Med): 8 studies with 464 patients -> NNT of 5 (CI 3 -10). 3. Lee et al. 2014 (J Neurogastro Motil): 7 studies with 374 patients -> significant reduction of IBS symptoms following hypnotherapy (standardized mean difference, -0. 83; 95% CI, -1. 65 to -0. 01).
Recent developments
Gut-directed hypnotherapy training now available for healthcare professionals in the Netherlands (course by Carla Flik)
Neurogastroenterol Motil. 2019 Feb 27: e 13573.
How to overcome these limitations? 1. Increase understanding about neurobiological background (to convince a broader audience of its efficacy) 2. Increase accessibility
Neuroimaging studies
Efficacy of online hypnotherapy vs. conventional hypnotherapy (FORTITUDE study) 3 -arm RCT, treatment period of 12 weeks - Hypnotherapy delivered by therapist - Online hypnotherapy - Online psycho-education (control arm) To be included: 285 (95 per arm)
https: //projects. invisionapp. com/share/MFPTZ 3 ACT 89#/scr eens/339314806 https: //www. gripopbuik. nl
Thank you for your attention d. keszthelyi@mumc. nl
- Slides: 21